| 产品名称： | SW756 |
|---|---|
| 商品货号： | TS210809 |
| Organism： | Homo sapiens, human |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | squamous cell carcinoma |
| Age： | 46 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | modal number = 76; range = 60 to 96 |
| Derivation： | Temple Texas, United States |
| Clinical Data： | female Caucasian 46 years |
| Antigen Expression： | HLA A1, A24, B8, B44, Cw2, Cx, DR6Y; Le3; Le4; Le5 |
| Genes Expressed： | HLA A1, A24, B8, B44, Cw2, Cx, DR6Y; Le3; Le4; Le5 |
| Tumorigenic： | Yes |
| Effects： | Yes, in nude mice |
| Virus Susceptibility： | Influenza A virus
,
Influenza A virus |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Leibovitzs L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. (Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation) |
| Subculturing： | Protocol: Remove medium, rinse with fresh 0.25% trypsin solution, remove trypsin and let the culture sit at room temperature until the cells detach. Add fresh medium, aspirate and dispense into new flasks. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended Medium Renewal: 2 to 3 times per week |
| Cryopreservation： | Freeze medium: culture medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 100% Temperature: 37.0°C |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 12,13 D5S818: 11,12 D7S820: 10,12 THO1: 9.3 TPOX: 8 vWA: 17 |
| Isoenzymes： | G6PD, B GLO-I, 1-2 |
| Name of Depositor： | Univ. Texas System, Board of Regents |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| Year of Origin： | 1974 |
| References： | Freedman RS, et al. Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses. US Patent 5,434,076 dated Jul 18 1995 Freedman RS, et al. Characterization of a cell line (SW756) derived from a human squamous carcinoma of the uterine cervix. In Vitro 18: 719-726, 1982. PubMed: 7129487 PR8/A/34 The SW756 cell line was initiated by A. Leibovitz at the Scott and White Clinic, Temple, Texas in 1974 from biopsy material from a poorly differentiated invasive squamous carcinoma of the uterine cervix. The patient had not received chemotherapy or radiation prior to the biopsy. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | SW756 |
|---|---|
| 商品货号： | TS210809 |
| Organism： | Homo sapiens, human |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | squamous cell carcinoma |
| Age： | 46 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | modal number = 76; range = 60 to 96 |
| Derivation： | Temple Texas, United States |
| Clinical Data： | female Caucasian 46 years |
| Antigen Expression： | HLA A1, A24, B8, B44, Cw2, Cx, DR6Y; Le3; Le4; Le5 |
| Genes Expressed： | HLA A1, A24, B8, B44, Cw2, Cx, DR6Y; Le3; Le4; Le5 |
| Tumorigenic： | Yes |
| Effects： | Yes, in nude mice |
| Virus Susceptibility： | Influenza A virus
,
Influenza A virus |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Leibovitzs L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. (Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation) |
| Subculturing： | Protocol: Remove medium, rinse with fresh 0.25% trypsin solution, remove trypsin and let the culture sit at room temperature until the cells detach. Add fresh medium, aspirate and dispense into new flasks. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended Medium Renewal: 2 to 3 times per week |
| Cryopreservation： | Freeze medium: culture medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 100% Temperature: 37.0°C |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 12,13 D5S818: 11,12 D7S820: 10,12 THO1: 9.3 TPOX: 8 vWA: 17 |
| Isoenzymes： | G6PD, B GLO-I, 1-2 |
| Name of Depositor： | Univ. Texas System, Board of Regents |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| Year of Origin： | 1974 |
| References： | Freedman RS, et al. Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses. US Patent 5,434,076 dated Jul 18 1995 Freedman RS, et al. Characterization of a cell line (SW756) derived from a human squamous carcinoma of the uterine cervix. In Vitro 18: 719-726, 1982. PubMed: 7129487 PR8/A/34 The SW756 cell line was initiated by A. Leibovitz at the Scott and White Clinic, Temple, Texas in 1974 from biopsy material from a poorly differentiated invasive squamous carcinoma of the uterine cervix. The patient had not received chemotherapy or radiation prior to the biopsy. |
